Headache News and Research

Latest Headache News and Research

Study of high school players find no link between years of play and decline in neurocognitive function

As more parents consider whether it's safe for adolescents to play football, a new Tulane University study of high school players found no link between years of play and any decline in neurocognitive function.

18 Mar 2014

Study finds no link between neurocognitive function and years of football play in adolescent athletes

A new study presented today at the 2014 Annual Meeting of the American Academy of Orthopaedic Surgeons found no link between neurocognitive function and years of football play in adolescent athletes.

14 Mar 2014

New insights into how human brain responds to chronic pain

University of Adelaide researchers say new insights into how the human brain responds to chronic pain could eventually lead to improved treatments for patients.

13 Mar 2014

Cefaly medical device receives FDA approval for migraine prevention

CEFALY Technology announced today that its received U.S. Food and Drug Administration approval of the Cefaly medical device for the preventative treatment for migraine headaches. Cefaly is the first transcutaneous electrical nerve stimulation (TENS) device specifically authorized for use prior to the onset of pain. It is expected to be available in the U.S. in early April.

13 Mar 2014

Orexo signs multi-year agreement with OptumRx and UnitedHealth Group

Orexo AB, the manufacturer of ZUBSOLV® (buprenorphine and naloxone) sublingual tablets (CIII), announced a multi-year agreement with UnitedHealth Group® and OptumRx® providing preferred coverage and reimbursement of ZUBSOLV®.

12 Mar 2014

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

10 Mar 2014

Conditioned pain modulation decreases activity in human spinal cord, say researchers

Researchers have demonstrated that conditioned pain modulation (CPM), a measure of the brain's ability to regulate pain, decreases activity in the human spinal cord as visible via functional magnetic resonance imaging (fMRI).

10 Mar 2014

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Incyte Corporation (Nasdaq: INCY) today announced that a pivotal Phase III trial of ruxolitinib compared to best available therapy in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea has met its primary endpoint of achieving phlebotomy independence and reducing spleen size by 35 percent or more.

7 Mar 2014

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Today Boehringer Ingelheim announced results from STARTVerso4 in patients with HCV/HIV co-infection. Hepatitis C viral cure 12 weeks after the conclusion of treatment (SVR12) was achieved by 72% of all patients in the trial. Patients were enrolled in either 120mg or 240mg faldaprevir dose groups.

6 Mar 2014

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Merck, known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor.

5 Mar 2014

Loyola physician sheds light on common and painful viral infection, shingles

Shingles is a painful viral infection that affects almost one million people worldwide and 30 percent of Americans every year.

4 Mar 2014

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

The first detailed results from AbbVie's pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference and will also be presented as a late-breaker at the conference on March 4.

4 Mar 2014

Dendreon plans to make PROVENGE available in Europe

Dendreon Corporation today announced that it plans to make PROVENGE (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning with Germany and the United Kingdom.

3 Mar 2014

Cedars-Sinai neurosurgeon successfully performs CSF repair surgery on patient

When Elizabeth "Beth" Johnson stood up from working at her computer Oct. 28, she noticed "a kind of funny feeling" in the back of her neck. By Nov. 2, the sensation had become an excruciating headache that came on whenever she tried to stand or sit upright.

28 Feb 2014

FDA approves KALYDECO for people with cystic fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.

26 Feb 2014

Nurses in emergency care must be trained to recognise symptoms of meningococcal septicaemia

Nurses working in emergency care environments must be trained to recognise the atypical signs and symptoms of meningococcal septicaemia.

26 Feb 2014

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved TIVORBEX™ (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), at 20 mg and 40 mg doses for the treatment of mild to moderate acute pain in adults.

25 Feb 2014

Onset Dermatologics launches 75mg strength of MINOCIN pellet-filled capsules to treat bacterial infections

Onset Dermatologics, a leader in developing and commercializing prescription products for improving skin health, today announced the launch of a 75mg strength of MINOCIN (minocycline hydrochloride) Pellet-Filled Capsules.

25 Feb 2014

FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the current label of XELJANZ® (tofacitinib citrate) 5 mg tablets to include radiographic data from two Phase 3 studies, ORAL Scan (A3921044) and ORAL Start.

25 Feb 2014

Dreams and delusions are associated with faulty "reality testing", shows research

New research from the University of Adelaide has delved into the reasons why some people are unable to break free of their delusions, despite overwhelming evidence explaining the delusion isn't real.

21 Feb 2014

Headache News and Research

Latest Headache News and Research

Study of high school players find no link between years of play and decline in neurocognitive function

Study finds no link between neurocognitive function and years of football play in adolescent athletes

New insights into how human brain responds to chronic pain

Cefaly medical device receives FDA approval for migraine prevention

Orexo signs multi-year agreement with OptumRx and UnitedHealth Group

Antares Pharma announces launch of OTREXUP to Dermatologists

Conditioned pain modulation decreases activity in human spinal cord, say researchers

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Loyola physician sheds light on common and painful viral infection, shingles

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

Dendreon plans to make PROVENGE available in Europe

Cedars-Sinai neurosurgeon successfully performs CSF repair surgery on patient

FDA approves KALYDECO for people with cystic fibrosis

Nurses in emergency care must be trained to recognise symptoms of meningococcal septicaemia

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

Onset Dermatologics launches 75mg strength of MINOCIN pellet-filled capsules to treat bacterial infections

FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

Dreams and delusions are associated with faulty "reality testing", shows research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in